A REVIEW OF OZEMPIC’S OFF LABEL USE FOR WEIGHT LOSS IN NON-DIABETIC INDIVIDUALS: CLINICAL EVIDENCE, SAFETY AND ETHICS
Abstract
Ozempic a GLP-1 Receptor agonist is formulated to treat type 2 diabetes mellitus, recently became one of the most famous medicine for weight loss due to endorsement of celebrities and viral marketing trends on social media. Ozempic acts by mimicking GLP-1 thus helping to reduce blood glucose, increase insulin production and by having a feeling of fullness. This article reviews the off-label use of Ozempic among individuals without diabetes mellitus, summarising the clinical experience and practical application of Ozempic from publications made from 2020 to 2026. Ozempic’s effectiveness in reality proven by weight loss and HbA1C improvement, the social media craze around it has led to serious shortage issues for diabetic patients. The medication is faced with the occurrence of physical symptoms such as Ozempic face, depression and thyroid cancer. Ozempic has become the centre of debate within society as a shortcut solution for weight loss.
Keywords
- Ozempic, weight loss, semaglutide, GLP-1 agonists, off-label use
Views & Downloads Statistics (Last 12 Months)
Monthly performance and trends of article views and downloads
